{"filing":{"accession_number":"0001193125-26-260679","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"d158334d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526260679/d158334d8k.htm"},"events":[{"id":6176,"run_id":5424,"accession_number":"0001193125-26-260679","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors, demonstrating strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. This clinical milestone data, which will advance the program to Phase 3 development, is material to investors' assessment of the company's pipeline and regulatory prospects.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5049,"accession_number":"0001193125-26-260679","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors via press release on June 8, 2026. While clinical trial results are material to biotech investors' assessment of pipeline progress and regulatory prospects, this disclosure does not fit the earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. The clinical data announcement is material but falls outside the defined categories, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:17:09.639842+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5050,"accession_number":"0001193125-26-260679","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports initial Phase 1/2 clinical trial data for vopimetostat in combination with RAS(ON) inhibitors, showing strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. While this is clinical trial data rather than a formal earnings release, M\u0026A activity, or other specifically-enumerated event type, the positive efficacy and safety results from a pivotal combination trial that will advance to Phase 3 development would materially affect a reasonable investor's assessment of the company's pipeline and prospects. This does not fit cleanly into the more specific categories but represents a material clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:17:09.639842+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5049,"accession_number":"0001193125-26-260679","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Tango Therapeutics disclosed initial safety and efficacy data from a Phase 1/2 combination trial of vopimetostat with RAS(ON) inhibitors via press release on June 8, 2026. While clinical trial results are material to biotech investors' assessment of pipeline progress and regulatory prospects, this disclosure does not fit the earnings_release category (which typically covers financial results) nor any other specific event type in the taxonomy. The clinical data announcement is material but falls outside the defined categories, warranting classification as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:17:09.639842+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-08"},{"id":5050,"accession_number":"0001193125-26-260679","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports initial Phase 1/2 clinical trial data for vopimetostat in combination with RAS(ON) inhibitors, showing strong efficacy signals (92% ORR in PDAC with daraxonrasib, 52% ORR with zoldonrasib) and favorable safety profiles. While this is clinical trial data rather than a formal earnings release, M\u0026A activity, or other specifically-enumerated event type, the positive efficacy and safety results from a pivotal combination trial that will advance to Phase 3 development would materially affect a reasonable investor's assessment of the company's pipeline and prospects. This does not fit cleanly into the more specific categories but represents a material clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:17:09.639842+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-08"}]}